Cancer Care Ontario | Cancer Care Ontario

Systemic Treatment Emergency Preparedness Guidance Document

Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Safe Administration of Systemic Cancer Therapy Part 2: Administration of Systemic Treatment and Management of Preventable Adverse Events

Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Cancer Care Ontario Bladder Cancer Guideline: An Endorsement of the 2017 American Urological Association Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA, ASCO, ASTRO, SUO Guide